Lux Biosciences Inc.

Ophthalmology-focused Lux Biosciences Inc. joins the ranks of recently founded in-licensers that have pulled down massive A-rounds on the back of management's track record and an in-licensed prospect. Lux's lead candidate is a calcineurin inhibitor; its initial target is uveitis.

299 Pavonia Avenue 3-8

Jersey City NJ 07302

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip